INNO Stock Overview
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InnoCan Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.28 |
| 52 Week High | CA$0.52 |
| 52 Week Low | CA$0.18 |
| Beta | 3.07 |
| 1 Month Change | -11.29% |
| 3 Month Change | -3.51% |
| 1 Year Change | 19.57% |
| 3 Year Change | -49.07% |
| 5 Year Change | n/a |
| Change since IPO | 10.00% |
Recent News & Updates
Recent updates
Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Dec 06
We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth
Aug 15Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth
Apr 19Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Jul 20We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully
Apr 05Shareholder Returns
| INNO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -6.6% | 0.7% |
| 1Y | 19.6% | 41.0% | 4.9% |
Return vs Industry: INNO underperformed the Canadian Pharmaceuticals industry which returned 54.7% over the past year.
Return vs Market: INNO exceeded the Canadian Market which returned 5.5% over the past year.
Price Volatility
| INNO volatility | |
|---|---|
| INNO Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: INNO has not had significant price volatility in the past 3 months.
Volatility Over Time: INNO's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Iris Bincovich | innocanpharma.com |
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
InnoCan Pharma Corporation Fundamentals Summary
| INNO fundamental statistics | |
|---|---|
| Market cap | CA$77.18m |
| Earnings (TTM) | -CA$6.42m |
| Revenue (TTM) | CA$18.66m |
4.1x
P/S Ratio-12.0x
P/E RatioIs INNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNO income statement (TTM) | |
|---|---|
| Revenue | US$13.66m |
| Cost of Revenue | US$1.68m |
| Gross Profit | US$11.98m |
| Other Expenses | US$16.68m |
| Earnings | -US$4.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 87.71% |
| Net Profit Margin | -34.41% |
| Debt/Equity Ratio | 0% |
How did INNO perform over the long term?
See historical performance and comparison